The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.
 
Qing Zhou
No Relationships to Disclose
 
Nong Yang
Consulting or Advisory Role - Hansoh Pharma
Research Funding - Hansoh Pharma
 
Jun Zhao
No Relationships to Disclose
 
Xiaorong Dong
No Relationships to Disclose
 
Huijuan Wang
No Relationships to Disclose
 
Ying Yuan
No Relationships to Disclose
 
Yan Yu
No Relationships to Disclose
 
Meijiang Zhang
Employment - Innovent Biologics
 
Sujie Zhang
Employment - Innovent Biologics
 
Mengna Huang
Employment - Innovent Biologics
 
Yuping Shen
Employment - Innovent Biologics
 
Yi-Long Wu
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)